Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 228

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial

Open access
Jones, Rachel B, Hiemstra, Thomas F, Ballarin, Jose, Blockmans, Daniel Engelbert, Brogan, Paul, Bruchfeld, Annette, Cid, Maria C, Dahlsveen, Karen, de Zoysa, Janak, Espigol-Frigolé, Georgína, Lanyon, Peter, Peh, Chen Au, Tesar, Vladimir, Vaglio, Augusto, Walsh, Michael, Walsh, Dorothy, Walters, Giles, Harper, Lorraine, Jayne, David · 2019 · Annals of the Rheumatic Diseases

Abstract

Objectives Cyclophosphamide induction regimens are effective for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but are associated with infections, malignancies and infertility. Mycophenolate mofetil (MMF) has shown high remission rates in small studies of AAV. Methods We conducted a randomised controlled trial to investigate whether MMF was non-inferior to cyclophosphamide for remission induction in AAV. 140 newly diagnosed patients were randomly assigned to MMF or pulsed cyclophosphamide. All patients received the same oral glucocorticoid regimen and were switched to azathioprine following remission. The primary endpoint was remission by 6 months requiring compliance with the tapering glucocorticoid regimen. Patients with an eGFR <15 mL/min were excluded from the study. Results At baseline, ANCA subtype, disease activity and organ involvement were similar between groups. Non-inferiority was demonstrated for the primary remission endpoint, which occurred in 47 patients (67%) in the MMF group and 43 patients (61%) in the cyclophosphamide group (risk difference 5.7%, 90% CI −7.5% to 19%). Following remission, more relapses occurred in the MMF group (23 patients, 33%) compared with the cyclophosphamide group (13 patients, 19%) (incidence rate ratio 1.97, 95% CI 0.96 to 4.23, p=0.049). In MPO-ANCA patients, relapses occurred in 12% of the cyclophosphamide group and 15% of the MMF group. In PR3-ANCA patients, relapses occurred in 24% of the cyclophosphamide group and 48% of the MMF group. Serious infections were similar between groups (26% MMF group, 17% cyclophosphamide group) (OR 1.67, 95% CI 0.68 to 4.19, p=0.3). Conclusion MMF was non-inferior to cyclophosphamide for remission induction in AAV, but resulted in higher relapse rate. Trial registration number NCT00414128.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2018-214245

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 228

Metadata

Authors
Jones, R. B., Hiemstra, T. F., Ballarin, J., Blockmans, D. E., Brogan, P., Bruchfeld, A., Cid, M. C., Dahlsveen, K., de Zoysa, J., Espigol-Frigolé, G., Lanyon, P., Peh, C. A., Tesar, V., Vaglio, A., Walsh, M., Walsh, D., Walters, G., Harper, L., & Jayne, D.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2019-03
Volume
78
Issue
3
Pages
399-405
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2908342189
Cited by
228
References
3
FWCI
23.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. https://app.cochat.ai/papers/10.1136/annrheumdis-2018-214245
The paper
Jones, R. B., Hiemstra, T. F., Ballarin, J., Blockmans, D. E., Brogan, P., Bruchfeld, A., Cid, M. C., Dahlsveen, K., de Zoysa, J., Espigol-Frigolé, G., Lanyon, P., Peh, C. A., Tesar, V., Vaglio, A., Walsh, M., Walsh, D., Walters, G., Harper, L., & Jayne, D. (2019). Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2018-214245

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.